RT Journal Article
SR Electronic
T1 Longitudinal analyses of depression and anxiety highlight greater prevalence during COVID-19 lockdowns in the Dutch general population and a continuing increase in suicidal ideation in young adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.02.22273554
DO 10.1101/2022.05.02.22273554
A1 Ori, Anil P. S.
A1 Wieling, Martijn
A1 Lifelines Corona Research Initiative
A1 van Loo, Hanna M.
YR 2022
UL http://medrxiv.org/content/early/2022/05/05/2022.05.02.22273554.abstract
AB Objective The pandemic of the coronavirus disease 2019 (COVID-19) has led to an increased burden on mental health. This study therefore investigated the development of major depressive disorder (MDD), generalized anxiety disorder (GAD), and suicidal ideation in the Netherlands during the first fifteen months of the pandemic and three nation-wide lockdowns.Methods Participants of the Lifelines Cohort Study –a Dutch population-based sample-reported current symptoms of MDD and GAD, including suicidal ideation, according to DSM-IV criteria using a digital structured questionnaire. Between March 2020 and June 2021, 36,106 participants (aged 18-96) filled out a total of 629,811 questionnaires across 23 time points. Trajectories over time were estimated using generalized additive models and analyzed in relation to age, sex, and lifetime history of MDD/GAD to identify groups at risk.Results We found non-linear trajectories for MDD and GAD with a higher number of symptoms and prevalence rates during periods of lockdown. The point prevalence of MDD and GAD peaked during the third hard lockdown at 2.88% (95% CI: 2.71%–3.06%) and 2.92% (95% CI: 2.76%-3.08%), respectively, in March 2021. Women, younger adults, and participants with a history of MDD/GAD reported significantly more symptoms. For suicidal ideation, we found a linear increase over time in younger participants which continued even after the lockdowns ended. For example, 4.63% (95% CI: 3.09%-6.96%) of 20-year-old participants reported suicidal ideation at our last measured time point in June 2021, which represents a 4.14x increase since the start of the pandemic.Conclusions Our study showed greater prevalence of MDD and GAD during COVID-19 lockdowns suggesting that the pandemic and government enacted restrictions impacted mental health in the population. We furthermore found a continuing increase in suicidal ideation in young adults. This warrants for alertness in clinical practice and prioritization of mental health in public health policy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHvL was supported by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation and a VENI grant from the Talent Programme of the Netherlands Organization of Scientific Research (NWO-ZonMW 09150161810021). The funding organizations had no impact on study design, data collection, analysis, or interpretation, or decision to submit the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Lifelines Cohort Study was approved by the Medical Ethical Committee of the University Medical Center Groningen.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were obtained from the Lifelines biobank under project application OV20_00021. Data can be obtained by submitting a request to the Lifelines Research Office (research{at}lifelines.nl). The data are not publicly available because they contain information that could compromise the study participants' privacy and consent. https://www.lifelines.nl/